Scarica l'app Stockscreener
63.35
4.25%
2.58
Dopo l'orario di chiusura:
62.50
-0.85
-1.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$60.77
Aprire:
$60.99
Volume 24 ore:
1.62M
Relative Volume:
0.81
Capitalizzazione di mercato:
$7.75B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-12.04
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
-3.53%
1M Prestazione:
-3.93%
6M Prestazione:
+90.81%
1 anno Prestazione:
+26.11%
Intervallo 1D:
$60.45
$63.80
Intervallo di 1 settimana:
$59.56
$66.37
Portata 52W:
$29.31
$69.33
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
63.35 | 7.43B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Frazier Life Sciences Management L.P. Invests $18.33 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - BioCentury
Cytokinetics receives positive EU opinion for MYQORZO in heart condition By Investing.com - Investing.com Canada
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Bakersfield.com
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
EMA committee recommends approval of Cytokinetics’ oHCM drug - Investing.com
Cytokinetics (CYTK) Receives Positive EU Recommendation for MYQO - GuruFocus
EMA committee recommends approval of Cytokinetics’ oHCM drug By Investing.com - Investing.com Australia
Cytokinetics receives positive EU opinion for MYQORZO in heart condition - Investing.com
Cytokinetics Receives Positive Opinion for MYQORZO® in EU - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion Of MYQORZO For The Treatment Of Obstructive Hypertrophic Cardiomyopathy - TradingView — Track All Markets
Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan
Cytokinetics (CYTK) Stock Rating Reiterated at 'Buy' by Needham - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Notice For Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $68,730 in shares - Investing.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - sharewise.com
Norges Bank Invests $39.12 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by CW Advisors LLC - MarketBeat
Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story (CYTK)? - simplywall.st
Brown Advisory Inc. Has $32.89 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock - MarketBeat
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock By Investing.com - Investing.com South Africa
Insider Sell: Andrew Callos Sells 52,486 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock - Investing.com India
Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - sharewise.com
Will Cytokinetics Incorporated (KK3A) stock issue positive guidanceJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Can Cytokinetics Incorporated (KK3A) stock double in coming years2025 Earnings Impact & Weekly Market Pulse Updates - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out - ACCESS Newswire
Is Cytokinetics Incorporated (KK3A) stock overpriced at current multiplesMarket Trend Report & Long-Term Capital Growth Ideas - Newser
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bakersfield.com
Attention Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Cytokinetics, Incorporated $CYTK Shares Sold by Schroder Investment Management Group - MarketBeat
Why analysts recommend Cytokinetics Incorporated (KK3A) stockJuly 2025 Market Mood & Low Drawdown Investment Strategies - Newser
What technical patterns form on Cytokinetics Incorporated (KK3A) stock chartsPortfolio Risk Summary & Short-Term Swing Trade Alerts - Newser
How Cytokinetics Incorporated (KK3A) stock trades under stagflation2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
Cytokinetics, Incorporated $CYTK Position Increased by American Century Companies Inc. - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,200 Shares - MarketBeat
Henderson, Cytokinetics director, sells $559k in stock By Investing.com - Investing.com South Africa
Edward Md Kaye Sells 28,064 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics, Incorporated $CYTK Stake Cut by Skandinaviska Enskilda Banken AB publ - MarketBeat
Can Cytokinetics Incorporated (KK3A) stock sustain margin levelsQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - Newser
Cytokinetics, Incorporated $CYTK Shares Sold by Fisher Asset Management LLC - MarketBeat
Will Cytokinetics Incorporated (KK3A) stock draw ESG focused fundsJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Dec 08 '25 |
Sale |
65.96 |
1,042 |
68,730 |
50,660 |
| Callos Andrew | EVP, Chief Commercial Officer |
Dec 05 '25 |
Option Exercise |
33.84 |
52,486 |
1,775,998 |
103,146 |
| Callos Andrew | EVP, Chief Commercial Officer |
Dec 05 '25 |
Sale |
65.95 |
52,486 |
3,461,452 |
50,660 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):